David Kendall Jung

Title: David Kendall Jung: Innovator in Receptor Tyrosine Kinase Inhibitors

Introduction

David Kendall Jung is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of receptor tyrosine kinase inhibitors. His work focuses on innovative compounds that have therapeutic potential in treating various disorders.

Latest Patents

David Kendall Jung holds a patent for "Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of Raf kinases." This patent includes compounds of general formula (I) wherein R is H or optionally joined with R to form a fused ring selected from the group consisting of five to ten membered aryl, heteroaryl, or heterocyclyl rings. The patent outlines the use of these compounds in therapy, especially in the treatment of disorders mediated by cRaf1 kinase. He has 1 patent to his name.

Career Highlights

David is currently associated with Glaxo Wellcome Inc., where he continues to advance his research and development efforts. His work has been instrumental in the exploration of new therapeutic avenues in the pharmaceutical industry.

Collaborations

Throughout his career, David has collaborated with esteemed colleagues, including Robert Neil Hunter, III and Philip Anthony Harris. These partnerships have fostered innovation and contributed to the success of his projects.

Conclusion

David Kendall Jung is a prominent figure in the field of receptor tyrosine kinase inhibitors, with a focus on developing innovative therapeutic compounds. His contributions to medicinal chemistry are noteworthy, and his ongoing work continues to impact the industry positively.